Detectable Vancomycin Stool Concentrations in Hospitalized Patients with Diarrhea Given Intravenous Vancomycin
Open Access
- 28 September 2023
- journal article
- research article
- Published by MDPI AG in Pharmacoepidemiology
- Vol. 2 (4) , 283-288
Abstract
Vancomycin is not appreciably passaged via the colonic membrane to the gastrointestinal (GI) tract in persons with an intact gut epithelium due to its large chemical structure. However; hospitalized patients with diarrhea often have a disrupted GI tract. The aim of this study was to determine the frequency of detectable vancomycin concentrations in the stool of patients with antibiotic-associated diarrhea receiving IV vancomycin. This was a multicenter cohort study of hospitalized patients with stool samples collected for Clostridioides difficile testing. Leftover stool samples were collected from patients who had received at least 3 days of IV vancomycin. Fecal vancomycin was quantified by high-performance liquid chromatography. The study cohort included 33 unique patients, majority female (54.5%) aged 60 years (range 23–84). Eighteen of thirty-three patients (54.5%) tested positive for C. difficile toxins. The average duration of systemic vancomycin administration prior to stool collection was 3.5 (range 2–15) days. Three of 33 (9%) stool samples had a detectable vancomycin concentration (range 1.2–13.2 mcg/mL). These concentrations may promote the development of vancomycin-resistant Enterococcus or van mutations in C. difficile, leading to vancomycin resistance. Further studies on implications are warranted.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (T32 AI141349, NIAID R01AI139261, G0507743, G0507861)
- ACCP Foundation Junior Investigator Research Award (T32 AI141349, NIAID R01AI139261, G0507743, G0507861)
- SIDP Early Career Research Award (T32 AI141349, NIAID R01AI139261, G0507743, G0507861)
This publication has 26 references indexed in Scilit:
- Risk Factors for Systemic Vancomycin Exposure Following Administration of Oral Vancomycin for the Treatment of Clostridium difficile InfectionPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infectionBMC Infectious Diseases, 2010
- Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft‐versus‐host disease of the gastrointestinal tractTransplant Infectious Disease, 2009
- Trends in Antibacterial Use in US Academic Health CentersArchives of internal medicine (1960), 2008
- Evidence for Biliary Excretion of Vancomycin into Stool during Intravenous Therapy: Potential Implications for Rectal Colonization with Vancomycin-Resistant EnterococciAntimicrobial Agents and Chemotherapy, 2004
- Effects of Antibiotics on Nosocomial Epidemiology of Vancomycin-Resistant EnterococciAntimicrobial Agents and Chemotherapy, 2002
- Effect of Antibiotic Therapy on the Density of Vancomycin-Resistant Enterococci in the Stool of Colonized PatientsNew England Journal of Medicine, 2000
- The Association Between Antecedent Vancomycin Treatment and Hospital-Acquired Vancomycin-Resistant EnterococciArchives of internal medicine (1960), 1999
- Systemic absorption of vancomycin.Journal of Clinical Pathology, 1995
- Pharmacokinetics of vancomycinJournal of Antimicrobial Chemotherapy, 1984